Antti Ahokas Selected Research

Anxiety Disorders (Anxiety Disorder)

1/2018	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
1/2017	Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
4/2014	Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
7/2012	Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
4/2010	Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
6/2009	The DSM-IV-based Generalized Anxiety Disorder Severity Scale: preliminary validation using data from a trial of agomelatine versus placebo.
12/2005	Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
10/2005	Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antti Ahokas Research Topics

Disease

8	Anxiety Disorders (Anxiety Disorder) 01/2018 - 10/2005
3	Major Depressive Disorder (Major Depressive Disorders) 10/2018 - 06/2013
1	Dizziness (Lightheadedness) 04/2010
1	Sleepiness 04/2010
1	Fatigue 04/2010
1	Headache (Headaches) 04/2010
1	Nausea 04/2010
1	Panic Disorder (Panic Attack) 10/2005
1	Social Phobia 10/2005
1	Inflammation (Inflammations) 01/2002
1	Schizophrenia (Dementia Praecox) 01/2002

Drug/Important Bio-Agent (IBA)

7	agomelatine (S20098)IBA 10/2018 - 06/2009
2	Escitalopram FDA Link 01/2018 - 01/2018
1	tianeptine (Stablon)IBA 01/2018
1	Quetiapine Fumarate (Seroquel)FDA Link 04/2010
1	Paroxetine (Paxil)FDA LinkGeneric 04/2010
1	deramciclaneIBA 12/2005
1	Venlafaxine Hydrochloride (Effexor)FDA LinkGeneric 10/2005
1	NeopterinIBA 01/2002
1	CytokinesIBA 01/2002

Therapy/Procedure

1	Therapeutics 10/2005